Health Economics›Multiple myeloma›Maintenance after first-line therapy

Maintenance after first-line therapy

Multiple myeloma · 29 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 12 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Thalidomide monotherapy Variant #03	—	R 614 268	540d	23.0 mo	—	2	R 1 228 537 PFS proxy	1
Daratumumab monotherapy Variant #03	—	R 366 888	28d	—	—	—	—	1
KRd Variant #05	—	R 185 594	28d	59.1 mo	—	65	R 12 063 627 PFS proxy	1
Carfilzomib and Lenalidomide (KR) Variant #01	—	R 65 018	28d	—	—	—	—	1
Thalidomide and Dexamethasone (TD) Variant #12	—	R 57 486	29d	36.0 mo	—	38	R 2 184 476 PFS proxy	—
Ixazomib monotherapy Variant #04	—	R 57 453	28d	22.0 mo	—	24	R 1 378 872 PFS proxy	2
Thalidomide and Prednisolone (TP) Variant #01	—	R 29 231	28d	—	—	—	—	1
Thalidomide and Prednisone (TP) Variant #01	—	R 16 710	28d	—	—	—	—	1
Lenalidomide and Dexamethasone (Rd) Variant #09	—	R 14 094	35d	~21.0 mo	~55.4 mo	~19	~R 267 783 PFS proxy · indirect	26
RVD Variant #01	—	R 10 486	28d	~43.0 mo	—	~47	~R 492 828 PFS proxy · indirect	9
Bortezomib monotherapy Variant #14	—	R 8 539	35d	~30.3 mo	—	~27	~R 230 565 PFS proxy · indirect	5
Bortezomib and Dexamethasone (Vd) Variant #01	—	R 8 080	28d	~9.4 mo	~38.7 mo	~11	~R 88 876 PFS proxy · indirect	10
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	41.0 mo	113.8 mo	14	R 89 057 PFS proxy	4
Isa-Rd Variant #01 Partial	—	R 5 619	28d	—	—	—	—	—
Bortezomib and Prednisone (VP) Variant #01	—	R 4 359	90d	—	—	—	—	—
VT Variant #01	—	R 3 153	14d	—	—	—	—	—
Interferon alfa-2b and Thalidomide Variant #01	—	R 2 085	7d	27.7 mo	—	121	R 252 320 PFS proxy	1
Dexamethasone monotherapy Variant #11	—	R 1 389	35d	—	—	—	—	—
Carfilzomib monotherapy N/A - secondary systemic drug	—	R 434	28d	—	~10.2 mo	—	—	1
Interferon alfa and Dexamethasone Variant #01	—	R 347	28d	—	—	—	—	—
Prednisolone monotherapy Variant #03	—	R 109	84d	—	—	—	—	1
Prednisone monotherapy Variant #11	—	R 22	7d	~2.2 mo	~14.1 mo	~10	~R 215 PFS proxy · indirect	8
Interferon alfa-2b and Prednisone Variant #01	—	R 6	7d	—	—	—	—	—
Lenalidomide and Prednisone (RP) N/A - secondary systemic drug	—	R 0	28d	37.5 mo	—	41	R 0 PFS proxy	1
Placebo Partial	—	—	—	22.2 mo	—	—	—	2
Interferon alfa monotherapy Variant #01 Partial	—	—	7d	—	—	—	—	—
Observation Partial	—	—	—	—	—	—	—	1
Interferon alfa-2b monotherapy Variant #01 Partial	—	—	28d	13.2 mo	—	15	—	1
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	~5.4 mo	~17.5 mo	~24	—	10

29 of 29 regimens shown